CY
Christopher Yea
Chief Development Officer

Christopher Yea insider trades: KalVista Pharmaceuticals (KALV) stock sales

Chief Development Officer, KalVista Pharmaceuticals Last trade May 27, 2026 57 Form 4 filings
$1.2M
Sold, last 12 months
8 sales
$0
Bought, last 12 months
0 buys
44
Open-market trades
since 2019
1
Company
last trade 2026

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Christopher reports to the SEC

Open-market buys and sales

44 trades reported on SEC Form 4, newest first

DateStockTypeValue
May 27, 2026KALV↓ Sell$905K
May 26, 2026KALV↓ Sell$53K
May 22, 2026KALV↓ Sell$63K
May 18, 2026KALV↓ Sell$30K
Feb 23, 2026KALV↓ Sell$68K
Feb 18, 2026KALV↓ Sell$17K
Nov 24, 2025KALV↓ Sell$58K
Nov 18, 2025KALV↓ Sell$39K
Aug 25, 2025KALV↓ Sell$26K
Aug 22, 2025KALV↓ Sell$31K
Aug 18, 2025KALV↓ Sell$35K
Jul 9, 2025KALV↓ Sell$475K
May 23, 2025KALV↓ Sell$22K
May 22, 2025KALV↓ Sell$28K
May 19, 2025KALV↓ Sell$31K
Feb 24, 2025KALV↓ Sell$19K
Feb 18, 2025KALV↓ Sell$26K
Nov 26, 2024KALV↓ Sell$19K
Nov 18, 2024KALV↓ Sell$67K
Aug 23, 2024KALV↓ Sell$24K
Aug 19, 2024KALV↓ Sell$85K
May 20, 2024KALV↓ Sell$137K
Feb 20, 2024KALV↓ Sell$170K
Feb 14, 2024KALV↓ Sell$599K
Nov 20, 2023KALV↓ Sell$59K
Aug 18, 2023KALV↓ Sell$77K
May 18, 2023KALV↓ Sell$26K
Feb 17, 2023KALV↓ Sell$21K
Nov 18, 2022KALV↓ Sell$6K
Aug 17, 2022KALV↓ Sell$17K
Nov 1, 2021KALV↓ Sell$90K
Aug 2, 2021KALV↓ Sell$103K
May 3, 2021KALV↓ Sell$124K
Feb 23, 2021KALV↓ Sell$504K
Oct 29, 2020KALV↓ Sell$87K
Oct 21, 2020KALV↓ Sell$249K
Oct 16, 2020KALV↓ Sell$16K
Feb 5, 2020KALV↓ Sell$2K
Dec 20, 2019KALV↓ Sell$45K
Dec 16, 2019KALV↓ Sell$80K
Jul 22, 2019KALV↓ Sell$135K
Apr 22, 2019KALV↓ Sell$192K
Jan 25, 2019KALV↓ Sell$93K
Jan 23, 2019KALV↓ Sell$32K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other KALV insiders

Open-market trades in the last 12 months

About Christopher Yea's insider trades

Christopher Yea is Chief Development Officer at KalVista Pharmaceuticals (KALV). Since Jan 23, 2019, Christopher has reported no open-market purchases and 44 sales worth $5.0M on SEC Form 4. In the last 12 months: 8 sales ($1.2M).

Their filings also include option exercises (35 filings), grants and awards (14 filings), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every KALV insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.